Sign up here and take full advantage of MicrobiomePost‘s features.

Home » Probiota Global 2022 highlights

Probiota Global 2022 highlights

Stephen Daniells (William Reed Business Media Ltd.) discusses what emerged at Probiota Global 2022.

Events, Industry

Staff editor

Most recent

Gastroenterology

Nosocomial infection risks in critical illness: the microbiota-immune metasystem connection

26 May 2023

Scientific research

Targeting gut microbiome for disease diagnosis and therapy

24 May 2023

Industry

Pre-hypertension: from Biofarma Group a nutraceutical solution to counteract it

23 May 2023

Industry

MASTERing food chain microbiomes – the webinar

23 May 2023

HCPs Area

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Cover instant book - Vaginome

Vaginome: understanding the vaginal microbiome. Questions & answers

Industry

Pre-hypertension: from Biofarma Group a nutraceutical solution to counteract it

MASTERing food chain microbiomes – the webinar

Read more about Events, Industry

Industry

Pre-hypertension: from Biofarma Group a nutraceutical solution to counteract it

23 May 2023

Industry

MASTERing food chain microbiomes – the webinar

23 May 2023

Industry

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

16 May 2023

Industry

Ode to the people – Declaration of intent by SynBalance

4 May 2023

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

Industry

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

28 April 2023

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

Industry

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

27 April 2023

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Industry

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

26 April 2023

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma

Industry

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® in a Phase 1b Clinical Trial in Melanoma

13 April 2023